Infinity Pharmaceuticals is a biopharmaceutical company focused on developing medicines for people with cancer. Co. is focused on eganelisib (IPI-549), an orally administered, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat a range of solid tumors and represents a potentially additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. It showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy. The INFI stock yearly return is shown above.
The yearly return on the INFI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INFI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|